Selection of antihypertensive drug treatment in primary health care;Seleccion del tratamiento farmacologico de la hipertension arterial en atencion primaria

Medicina Clinica

Volumn 114, Issue 10, 2000, Pages 374-377

  Laporte, J R ^a  

^a Fundacion Institut Catala de Farmacologia   (Spain)

Author keywords

Antihypertensive treatment; Pharmacologic treatment; Primary health care

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTERY DISEASE; ARTICLE; ASTHMA; ATRIOVENTRICULAR BLOCK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EXAMINATION; DRUG CONTRAINDICATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIMARY HEALTH CARE; RISK ASSESSMENT; SPAIN; TREATMENT PLANNING;

EID: 0034681818     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(00)71301-7     Document Type: Article

References (16)

1. Kannel WB. Blood pressure as a cardiovascular risk factor. JAMA 1996; 275: 1571-1576.
2. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Defection Evaluation and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 1997; 157: 2413-2446.
3. Siegel D, López J. Trends in antihypertensive drug use in the United States JAMA 1997; 278: 1745-1748.
4. Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyt-Tere M et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985; 1: 1349-1354.
5. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285.
6. Pffefer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement Trial (SAVE). N Engl J Med 1992; 327: 669-677.
7. Lewis EJ, Hunsicker LG, Bain RP, Ronde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
8. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
9. Bloqueadores de los canales de calcio: novedades sobre su (in)efectividad e (in)seguridad. Butlletí Groc 1998; 11: 9-16.
10. Prieto M, De Abajo FJ, Montero D, Martín-Serrano G, Madurga M, Palop R. Uso de antihipertensivos en España, 1985-1995. Med Clin (Barc) 1998; 110: 247-253.
11. Capellà D, Porta M, Laporte JR. Utilization of antihypertensive drugs in certain European countries. Eur J Clin Pharmacol 1983; 25: 431-435.
12. Arnau JM, Bordas JM, Casajuana J, Diogène E, Hernéndez E, Llop R et al (Grupo de Estudio de la Prescripción en Atención Primaria-GEPAP). Variabilidad de la prescripción en indicaciones prevalantes en atención primaria: un estudio multicéntrico. Aten Primaria 1998; 22: 417-423.
13. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H et al, for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Advantage of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension, JAMA 1996; 276: 1886-1892.
14. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA 1998; 279: 1813-1816.
15. Moser M, Ross H. The treatment of hypertension in diabetic patients. Diabetes Care 1993; 16: 542-547.
16. Pahor M, Kritchevsky SB. Zuccalà G, Guralnik JM. Diabetes and risk of adverse events with calcium antagonists. Diabetes Care 1998; 21: 193-194.